Role of monocyte cytotoxic factor in cytolysis of actinomycin D-treated WEHI 164 cells mediated by freshly isolated human adherent mononuclear blood cells
- PMID: 3524816
Role of monocyte cytotoxic factor in cytolysis of actinomycin D-treated WEHI 164 cells mediated by freshly isolated human adherent mononuclear blood cells
Abstract
The role of the monocyte cytotoxic factor (CF) in cytolysis of untreated and actinomycin D (Act D)-treated WEHI 164 cells by freshly isolated human adherent mononuclear cells has been investigated in this study. Murine WEHI 164 cells were used as target cells because of their sensitivity to lysis mediated by monocytes and their resistance to natural killer cells. Monocytes as well as monocyte supernatants mediated cytolysis of WEHI 164 cells. Cytolysis was enhanced by Act D treatment of target cells. The addition of lipopolysaccharide to monocytes accelerated the progression of cytolysis of Act D-treated WEHI 164 cells mediated by monocytes. A polyclonal rabbit antiserum against CF inhibited the cytolytic activity of monocytes and monocyte supernatants against untreated as well as Act D-treated WEHI 164 cells. At low effector:target ratios, the cytolysis was totally abrogated by CF antiserum. Depletion of natural killer cells from adherent cells by the monoclonal antibody Leu 11b and rabbit complement did not reduce cytolysis of Act D-treated WEHI 164 cells. Immunofluorescence microscopy revealed that CF antiserum stained the plasma membrane of freshly isolated monocytes, suggesting that CF is a membrane-associated molecule. Our data indicate that CF is an important effector molecule in cytolysis mediated by freshly isolated monocytes against untreated and Act D-treated WEHI 164 cells.
Similar articles
-
Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity.Cancer Res. 1986 Nov;46(11):5947-52. Cancer Res. 1986. PMID: 3756932
-
Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.J Immunol. 1984 Feb;132(2):936-44. J Immunol. 1984. PMID: 6690624
-
Lipopolysaccharide (LPS) stimulates fresh human monocytes to lyse actinomycin D-treated WEHI-164 target cells via increased secretion of a monokine similar to tumor necrosis factor.J Immunol. 1985 Dec;135(6):3978-87. J Immunol. 1985. PMID: 3905966
-
Role of NK cell cytotoxic factor against fresh human tumors.Nat Immun. 1993 Jul-Oct;12(4-5):267-78. Nat Immun. 1993. PMID: 8257831 Review.
-
[Monocyte-macrophage activation syndrome].Pediatrie. 1988;43(4):297-300. Pediatrie. 1988. PMID: 3047660 Review. French.
Cited by
-
A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion.Invest New Drugs. 1992 Aug;10(3):183-90. doi: 10.1007/BF00877244. Invest New Drugs. 1992. PMID: 1428728 Clinical Trial.
-
Tumour necrosis factor-like activity on paraformaldehyde-fixed monocyte monolayers.Immunology. 1987 Aug;61(4):443-8. Immunology. 1987. PMID: 3443451 Free PMC article.
-
Design of a stable cell line producing a recombinant monoclonal anti-TNFα antibody based on a CHO cell line.Springerplus. 2016 Sep 15;5(1):1584. doi: 10.1186/s40064-016-3213-2. eCollection 2016. Springerplus. 2016. PMID: 27652157 Free PMC article.